drugset / Trial / NCT04792385
Safety, Compliance and Pharmacokinetics of Estetrol Monohydrate/Drospirenone 15/3 mg in Post-menarchal Female Adolescents
NaSingle-groupOpen-labelPrevention
Summary
To evaluate the safety, compliance, and pharmacokinetics profile of estetrol monohydrate (E4) 15 mg combined with drospirenone (DRSP) 3 mg in post-menarchal participants between the age of 12 and 17 years + 2 months.
Timeline
- Start
- 2020-12-28
- Primary completion
- 2023-11-24
- Completion
- 2023-11-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ESTETROL ANHYDROUS | Other / unclassified | 15 mg | Oral |
| Subject | drospirenone | Unknown | 3 mg | Oral |
Indications
No indication recorded.